List of large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US6054297 | GENENTECH, INC. | Humanized antibodies and methods for making them |
Feb, 2018
(5 years ago) | |
| US9795672 | GENENTECH, INC. | Treatment with anti-VEGF antibodies |
May, 2024
(7 months from now) | |
| US7485704 | GENENTECH, INC. | Reducing protein A leaching during protein A affinity chromatography |
Mar, 2025
(1 year, 5 months from now) | |
| US10906986 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(4 years from now) | |
| US11078294 | GENENTECH, INC. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Jul, 2028
(4 years from now) | |
| US8460895 | GENENTECH, INC. | Method for producing recombinant proteins with a constant content of pCO2 in the medium |
Mar, 2029
(5 years from now) | |
| US9714293 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(6 years from now) | |
| US10982003 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Aug, 2030
(6 years from now) | |
| US8512983 | GENENTECH, INC. | Production of proteins in glutamine-free cell culture media |
Jan, 2031
(7 years from now) | |
| US10662237 | GENENTECH, INC. | Method to improve virus filtration capacity |
May, 2031
(7 years from now) | |
| US10011856 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
May, 2031
(7 years from now) | |
| US10704071 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by down regulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Aug, 2031
(7 years from now) | |
| US9487809 | GENENTECH, INC. | Decreasing lactate level and increasing polypeptide production by downregulating the expression of lactate dehydrogenase and pyruvate dehydrogenase kinase |
Jan, 2032
(8 years from now) | |
| US10513697 | GENENTECH, INC. | CO2 profile cultivation |
Sep, 2032
(8 years from now) | |
| US10906934 | GENENTECH, INC. | Protein purification methods |
Oct, 2033
(10 years from now) | |
| US10676710 | GENENTECH, INC. | Cell culture compositions with antioxidants and methods for polypeptide production |
Mar, 2034
(10 years from now) | |
| US9441035 | GENENTECH, INC. | Cell culture media and methods of antibody production |
Apr, 2034
(10 years from now) | |
| US10274466 | GENENTECH, INC. | Elucidation of ion exchange chromatography input optimization |
Jul, 2035
(11 years from now) | |
| US10208355 | GENENTECH, INC. | Method of treatment for glioblastoma by administering a VEGF antagonist |
Jul, 2035
(11 years from now) | |
| US10336983 | GENENTECH, INC. | Method for increasing the specific production rate of eukaryotic cells |
Jul, 2035
(11 years from now) |
Ingredients: RECOMBINANT HUMANIZED MONOCLONAL IGG1 ANTIBODY
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic